FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
July 24, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the...
Dec 14, 2015
139
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly...
Dec 13, 2015
231
FDA Approved for RRMM: Daratumumab (Darzalex)
HORSHAM, PA, November 16, 2015 – Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S....
Dec 12, 2015
66
FDA Approved for NDMM: Lenalidomide (Revlimid)
SUMMIT, N.J., February 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug...
Dec 12, 2015
33
Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests
Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests https://myeloma.ca/pixms/uploads/serve/ckeditor/understanding...
Dec 11, 2015
109
Myeloma UK - Myeloma Animations Series: Clonal evolution: the changing nature of myeloma
Myeloma UK - Myeloma Animations Clonal evolution: the changing nature of myeloma Learn More: https://www.myeloma.org.uk/
Dec 11, 2015
116
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...
Dec 10, 2015
174
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas,...
Dec 10, 2015
177
FDA Approved for RRMM: Pomalidomide (Pomalyst) + Dexamethasone
April 23, 2015; SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it has fulfilled the accelerated...
Dec 10, 2015
89
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study
MMY1004 (PAVO) Study RRMM The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and...
Dec 9, 2015
291
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma Open-label, single-center, pilot study to assess the safety and feasibility...
Dec 9, 2015
141
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
EMN12/HOVON129 Study Phase 2: To evaluate progression-free survival in adult pPCL patients by incorporation of carfilzomib and...
Dec 9, 2015
111
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...
Dec 4, 2015
273
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...
Dec 3, 2015
282
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients
An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...
Dec 1, 2015
192
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
MMY3003 (POLLUX) Study NCT02076009: Phase 3: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and...
Dec 19, 2014
394
Myeloma UK - Myeloma Animations Series: High Dose Therapy and Autologous Stem Cell Transplantation
Myeloma UK - Myeloma Animations High Dose Therapy and Autologous Stem Cell Transplantation Learn More: https://www.myeloma.org.uk/
Dec 18, 2014
61
14th International Myeloma Workshop: April 3rd-7th, 2013 Kyoto, Japan
14th International Myeloma Workshop April 3rd-7th, 2013 Kyoto, Japan https://www.myelomasociety.org/publications/ 14th IMW Abstract Book:...
Dec 18, 2014
115
Charlotte Radiology: Port Placement: Dr. Eric Wang
Charlotte Radiology: Port Placement: Dr. Eric Wang
Dec 18, 2014
133
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
IFM2014-02 NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With...
Dec 17, 2014
78
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple...
Dec 17, 2014
45
NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1
DREAMM-1 study Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity...
Dec 16, 2014
228
Myeloma UK - Myeloma Animations Series: Myeloma Kidney Disease
Myeloma UK - Myeloma Animations Myeloma Kidney Disease Learn More: https://www.myeloma.org.uk/
Dec 16, 2014
55
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...
Dec 14, 2014
53